Literature DB >> 171057

Preoperative irradiation of cancer of the lung: final report of a therapeutic trial. A collaborative study.

J Warram.   

Abstract

Between May, 1963 and December, 1966, 17 medical centers cooperated in two separate but integrated therapeutic trials of primary lung cancer. One study was of patients with lesions considered operable at the time of diagnosis, and the other of patients with initially inoperable cancer but who were considered potentially operable after radiotherapy. Patients operable at the time of diagnosis were randomly assigned to receive either immediate surgery (278 patients) or preoperative radiotherapy followed by surgery (290 patients). All but one were followed until death or 5 years survival. Survival to each anniversary after randomization was almost identical for the two groups. At 5 years the survival rate was 14% after preoperative radiotherapy and 16% after immediate surgery. On the basis of the small standard error of the difference between these survival rates, a large advantage or a large disadvantage for preoperative radiotherapy is unlikely. Recurrence of cancer either locally or as distant metastasis was also similar in the two groups. Postoperative mortality was estimated to be 11% in the immediate surgery group, but cannot be estimated in a comparable fashion for the irradiated group. Certain postoperative complications were more frequent in the irradiated group, but survival during the first was not affected. Out of 425 patients initially considered to be inoperable, 152 were considered resectable after radiotherapy. These patients were randomly assigned to have either a thoracotomy and resection of their cancer if possible (78 patients) or no surgery (74 patients). Survival to each anniversary after randomization was very similar. After 5 years the survival rate was 8% for the group assigned to surgery and 6% for the group assigned to no surgery. The difference has a standard error of 4%.

Entities:  

Mesh:

Year:  1975        PMID: 171057     DOI: 10.1002/1097-0142(197509)36:3<914::aid-cncr2820360312>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

Review 1.  Induction chemotherapy or chemoradiotherapy before surgery for non-small-cell lung cancer.

Authors:  K S Albain
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

Review 2.  Management of lung cancer.

Authors:  A Melville; A Eastwood
Journal:  Qual Health Care       Date:  1998-09

3.  When in doubt should we cut it out? The role of surgery in non-small cell lung cancer.

Authors:  J-E C Holty; M K Gould
Journal:  Thorax       Date:  2006-07       Impact factor: 9.139

Review 4.  Neoadjuvant and adjuvant therapy in the management of locally advanced non-small-cell lung cancer.

Authors:  M T Jaklitsch; G M Strauss; D J Sugarbaker
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

Review 5.  The management of lung cancer.

Authors:  S G Spiro
Journal:  Lung       Date:  1982       Impact factor: 2.584

Review 6.  Radiotherapy in the management of non-small-cell lung cancer.

Authors:  A Bezjak; D Payne
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

7.  Preoperative concurrent radiochemotherapy and surgery for stage IIIA non-small cell lung cancer.

Authors:  Min Kyu Kang; Yong Chan Ahn; Do Hoon Lim; Keunchil Park; Joon Oh Park; Young Mog Shim; Jhingook Kim; Kwhanmien Kim
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153

Review 8.  Neoadjuvant radiotherapy/chemoradiotherapy in locally advanced non-small cell lung cancer.

Authors:  Deniz Yalman
Journal:  Balkan Med J       Date:  2015-01-01       Impact factor: 2.021

Review 9.  Update in cancer chemotherapy, Part III: Lung cancer, Part 1.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1985-10       Impact factor: 1.798

Review 10.  Current options in the treatment of non-small cell lung cancer.

Authors:  D Faulds
Journal:  Drugs       Date:  1992       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.